Indications & Dose: OSTEOPOROSIS PO Adult IR tablet: 35mg weekly once in males | OSTEOPOROSIS DRUG INDUCED PO Adult Prevention & treatment: 5mg OD | OSTEOPOROSIS IN POSTMENOPAUSAL PO Adult IR tablet: Prevention & treatment: 5mg OD or 35mg weekly once or 150mg monthly once, Delayed release tablet: 35mg weekly once | PAGET’S DISEASE OF BONE PO Adult 30mg OD 2 month, re-treatment may be considered if relapse occurs or treatment fails to normalize serum alkaline phosphatase

Precautions: Hepatic/renal impairment, hypotension, difficulty in swallowing, hypocalcemia

ADR: Serious: electrolyte disturbances, HTN, increase PTH levels, arthralgia, arrhythmia, prostatic hyperplasia, nephrolithiasis, bronchitis, myalgia, Others: neck pain, muscle spasm, cataract, nausea, constipation, dyspepsia, flu-like syndrome

DDI: Serious Aminoglycosides causes additive hypocalcemic effects, NSAIDs increases GI/renal adverse effects

Diet: Early morning on empty stomach(with 180ml of water)

Monitor: BMD of hip/spine before therapy, annual measurements of height & weight, assessment of chronic back pain, serum Ca, biochemical markers of bone turnover